NASDAQ: XXII
- Last Close 0.59
- Sector Consumer Defensive
- Industry Tobacco
- Investment Style Small Growth
- Day Range 0.58 – 0.62
- Year Range 0.58 – 2.70
- Market Cap 131.5891 Mil
- Volume / Avg 7,848.0 / 1.1 Mil
- Price / Sales 1.62
- Price / Book 1.62
- Forward Div Yield —
- Trailing Div Yield —
Morningstar‘s Stock Analysis XXII
1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile XXII
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has two operating segments; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain 95% less nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM, and The hemp/cannabis segment is engaged in providing hemp-derived cannabinoid ingredients and API, as well as a CDMO to the consumer goods industry. It derives a majority of its revenue from the tobacco segment.
Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.
22nd Century Group Inc
XNAS: XXII
| Charlies Holdings Inc
PINX: CHUC
| Rafarma Pharmaceuticals Inc
PINX: RAFA
| Kaival Brands Innovations Group Inc
XNAS: KAVL
| |
Price
| 0.59 | 0.08 | 0.27 | 0.70 |
Currency
| USD | USD | USD | USD |
Change
| −$0.02 (2.68%) | −$0.01 (10.44%) | −$0.01 (2.70%) | +$0.04 (6.06%) |
Market Cap
| 131.59 Mil | 18.10 Mil | 22.64 Mil | 39.32 Mil |
Industry
| Tobacco | Tobacco | Drug Manufacturers - Specialty & Generic | Tobacco |
Sector
|
Consumer Defensive
|
Consumer Defensive
|
Healthcare
|
Consumer Defensive
|
* Trading data in this section is delayed by at least 15 minutes.
FAQs for 22nd Century Group Inc Stock
No. XXII does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
XXII’s market cap is 131.59 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.
It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the
largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
XXII’s stock style is Small Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns.
Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
XXII’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare XXII’s historical performance against its industry peers and the overall market.